COLUMBIA, Md., Sept. 1 /PRNewswire-FirstCall/ -- Martek Biosciences Corporation (Nasdaq: MATK) today announced its financial results for the third quarter of fiscal 2010. Revenues for the third quarter were $117.2 million, up 51% from $77.8 million in the third quarter of fiscal 2009. GAAP net income was $11.9 million, or $0.35 per diluted share, for the third quarter of fiscal 2010, an increase of 33% compared to $8.9 million, or $0.27 per diluted share, for the third quarter of fiscal 2009. The revenues and earnings for the third quarter of fiscal 2010 include the results of Amerifit Brands ("Amerifit" or "branded consumer health products"), the acquisition of which was completed by Martek on February 12, 2010.
The third quarter of fiscal 2010 included charges related to the acquisition of Amerifit of $700,000 and charges related to the Winchester restructuring (see discussion below) of $600,000. Excluding these amounts, net of tax, the fiscal 2010 third quarter earnings on a non-GAAP basis would have been $12.7 million, or $0.38 per diluted share, an increase of 42% over the third quarter of fiscal 2009 (see Table II "Reconciliation of GAAP to Non-GAAP Net Income Measure" below).
Commenting on the quarter, Chief Executive Officer Steve Dubin said, "Martek's strong third quarter results reflect another good quarter for DHA and ARA sales to our infant formula customers, another record quarter of DHA sales in non-infant formula markets, strong sales of Amerifit's consumer branded products and improved gross margins. I believe that Martek's strong run rate coming out of fiscal 2010 will provide an excellent platform from which to grow as we continue to expand our DHA ingredients business beyond infant formula, begin to commercialize new products currently in development as consumer branded products sold through Amerifit's marketing and distribution channels and continue our efforts to reduce production costs. Accordingly, I expect growth in revenues, margin and earnings in 2011. It is also worth noting that, as a result of our strong earnings and robust cash flow generation, our Amerifit acquisition debt has been repaid earlier than expected and Martek is once again essentially debt-free. Martek's solid balance sheet and strong financial performance provides us with great flexibility which, among other things, should allow us to launch new Martek products, as noted above, during our next fiscal year, continue to prudently invest in our promising R&D pipeline and explore new complementary business opportunities."
Revenue Summary Product sales in the third quarter of fiscal 2010 were $114 million, an increase of $38.9 million from the third quarter of fiscal 2009. This increase was partially attributable to the branded consumer health product sales of Amerifit which totaled $20.3 million in the third quarter. The remainder of the increase, or $18.6 million, was the result of sales of our nutritional ingredients in both the infant formula and non-infant formula markets. Demand increases outside the United States, particularly in Asia, were a key driver of the growth in both markets.
A breakdown of product sales for the third quarter and fiscal year to date periods (in thousands) follows: Three months ended July 31,Nine months ended July 31,20102009% incr (decr)20102009%incr (decr)Nutritional ingredients:Infant formula
10%Food and beverage4,5532,681
60%Pregnancy and nursing, nutritional supplements and animal nutrition 9,0157,931
24%Shipping charges 624470
26%Total nutritional ingredients93,36174,402
13%Branded consumer health 20,301—
(18%) Total product sales
28%Contract manufacturing and collaborations revenues in the third quarter totaled $3.2 million, of which approximately $900,000 relates to revenues associated with Martek's joint development agreement with a subsidiary of BP p.l.c. ("BP") for work on microbial oils for use as biofuels and the remaining $2.3 million relates to contract manufacturing activities. Consistent with previous disclosures, as of July 31, 2010, we have ceased nearly all contract manufacturing activities.
Gross Margin and Operating Expenses Overall gross margin for the third quarter of fiscal 2010 was nearly 50%, an increase over the 44% gross margin realized in the third quarter of fiscal 2009. This improvement was largely due to both ARA and DHA cost reductions in the 2010 period and the positive impact of higher gross margins on branded consumer health product sales. Included in the third quarter's gross margin is the negative effect of approximately $200,000 (gross margin impact of 0.2%) related to one-time inventory step-up costs resulting from the Amerifit acquisition.Research and development expenses in the third quarter of fiscal 2010 were $8.5 million, consistent with previously stated guidance and up from $6.6 million in last year's third quarter. As anticipated, the increase was due to the volume of the Company's pre-clinical research activities during the current quarter, primarily associated with the development of Martek's next generation DHA product for infant formula, as well as higher personnel costs. Martek's research and development focuses on both broadening the market applications for life'sDHA™ as well as leveraging the Company's microbial technology platform to develop new high-value product offerings. The Company continues to expect quarter-to-quarter fluctuations in research and development expenses mainly due to the timing of outside services, including third-party clinical trial services.
During the third quarter of fiscal 2010, selling, general and administrative expenses were $18.9 million, or 16% of revenue, consistent with prior guidance and an increase from $11.0 million, or 14% of revenue, in last year's third quarter due partially to the incremental expenses attributable to Amerifit.Advertising and promotion costs during the third quarter totaled $5.6 million, or 5% of revenue. As a percentage of revenue, we anticipate similar advertising and promotion expenses for our current products each quarter, with such costs fluctuating from quarter to quarter due to the timing of particular advertising and promotional campaigns and the launch of new branded consumer health products.
Financial Position As previously noted, Martek financed its February 2010 acquisition of Amerifit through available cash, a new term debt facility totaling $75 million, and $11 million drawn from a new revolving credit facility. Strong cash generation since the acquisition, including over $36 million in the third quarter of fiscal 2010, enabled a full repayment of all acquisition financing within five months of the acquisition date. As such, as of July 31, 2010, the Company returned to being essentially debt-free and now has its entire $100 million credit line available.
Restructuring of Winchester Manufacturing SiteIn June 2010, Martek announced plans to restructure its Winchester, Kentucky manufacturing facilities in an effort to streamline operations, improve capacity utilization, and reduce manufacturing costs and operating expenses. As a result of this restructuring plan, a charge of approximately $600,000 was recorded in the third quarter of fiscal 2010 related to employee separation costs. The Company anticipates incurring approximately $1.0 million of additional restructuring costs in the fourth quarter of fiscal 2010 related to employee separation costs. Also, as previously announced, Martek is evaluating the potential sale or lease of a portion of its Winchester operations. Any such sale or lease would be contingent upon Martek's ability to maintain necessary production redundancies through continuing access to certain key processes at the Winchester facility and/or arrangements with contract manufacturers. We expect that the plant restructuring will result in a non-cash asset impairment charge or loss upon sale of $30 million to $40 million in the fourth quarter of fiscal 2010.
Significant Recent Events
Financial GuidanceThe projected results are shown below for Martek (not including Amerifit), Amerifit (stand-alone, post-acquisition) and on a consolidated basis for the three months ending October 31, 2010. The consolidated net income and earnings per share information is shown inclusive of any charges resulting from the Winchester restructuring described above as well as exclusive of such charges through the pro forma non-GAAP disclosures shown below. Three months ending October 31, 2010(in millions, except per share data)
87.0 – 91.0
21.0 – 22.0
108.0 – 113.0Income (loss) from operations before restructuring charge
16.1 – 18.3
3.0 – 3.5
19.6 – 21.8Restructuring charge
41.0 – 31.0
41.0 – 31.0Income (loss) from operations after restructuring charge
(24.9) – (12.7)
3.0 – 3.5
(21.4) – (9.2)Net income $
(13.4) – (5.9)Pro forma non-GAAP net income (a)$
11.8 – 13.1Diluted EPS$
(0.40) – (0.18)Pro forma non-GAAP diluted EPS (a)$
0.35 – 0.39(a) Excludes estimated charges of between $25.2 million and $19.0 million, net of tax ($41 million to $31 million, gross) related to the Winchester plant restructuring. See Table II "Reconciliation of GAAP to Non-GAAP Net Income Measure" below. For the fourth quarter of fiscal 2010, Martek expects infant formula revenue to be between $71 million and $75 million, non-infant formula nutritional revenue to be between $13 million and $14 million, and contract manufacturing and collaborations revenue to be between $1.0 million and $1.3 million. Such projected fourth quarter revenues would equate to year-over-year growth of more than 23%.
Consolidated gross margin in the fourth quarter of fiscal 2010 is expected to be between 51% and 52%. Furthermore, due to the Company's early repayment of its term loan and related debt issuance cost amortization acceleration in the third quarter, we expect interest expense to decline significantly in the fourth quarter of fiscal 2010 as compared to the third quarter of 2010.
Based on this fourth quarter guidance, Martek expects full fiscal year 2010 revenue to be between $439 million and $444 million, including infant formula revenues of between $308 million and $312 million. The projected 2010 annual revenues would represent year-over-year growth in total revenues of 27% to 29% (10% to 11% excluding Amerifit-related revenues) and reflects meaningful gains in nearly all markets for our nutritional ingredients, including growth in infant formula revenues of 8% to 9% and growth in non-infant formula nutritional revenues of 31% to 34%.
With the recently-extended infant formula supply agreements along with the pending Winchester restructuring, the Company has greater visibility into its expected results for fiscal 2011. As such, we are projecting revenue and net income growth over fiscal 2010. Contributing to this anticipated earnings increase is projected gross margin growth of at least 400 basis points over the expected full year fiscal 2010 level. Gross margin for fiscal 2011 will be favorably impacted by a full year of Amerifit operations, the discontinuation of the Company's low margin contract manufacturing business, production cost efficiencies and lower ARA pricing.
Investor Conference Call WebcastMartek will host a conference call and webcast for investors to review its third quarter results and fourth quarter of fiscal 2010 outlook at 4:45 p.m. Eastern Time on September 1, 2010. Access to the live audio webcast is available through Martek's website at http://investors.martek.com. The webcast will be available for replay for 30 days.
Cautionary Note Regarding Forward-Looking Statements Sections of this release contain forward-looking statements concerning, among other things: (1) Martek's expectations regarding future revenue growth in and customer demand from the infant formula, pregnancy and nursing, nutritional supplements, animal feeds and food and beverage markets as well as markets for Amerifit products; (2) its expectations regarding revenue, gross margin, operating expenses and income for the fourth quarter of and full year fiscal 2010 for both Martek and Amerifit; (3) its expectations regarding revenue, gross margin and income for fiscal 2011; (4) its expectations regarding launches by customers of products containing Martek's life'sDHA™ and future revenues associated with Martek's contract manufacturing; (5) its expectations regarding future capabilities of and benefits from the Amerifit acquisition; and (6) its expectations regarding charges to be recorded in the fourth quarter of fiscal 2010 related to the restructuring of the Winchester plant. Furthermore, Martek's operating results are subject to quarter-to-quarter fluctuations, some of which may be significant, and are also subject to future changes in the Company's preliminary purchase price allocation for its Amerifit acquisition. The forward-looking statements noted above are based upon numerous assumptions which Martek cannot control and involve risks and uncertainties that could cause actual results to differ. These statements should be understood in light of the risk factors and cautionary statements set forth herein and in the Company's filings with the Securities and Exchange Commission, including, but not limited to, Part I, Item 1A of the Company's Form 10-K for the fiscal year ended October 31, 2009 and other filed reports on Form 10-K, Form 10-Q and Form 8-K.
About MartekMartek Biosciences Corporation (Nasdaq: MATK) is a leader in the innovation, development, production and sale of high-value products from microbial sources that promote health and wellness through nutrition. The Company's technology platform consists of its core expertise, broad experience and proprietary technology in areas such as microbial biology, algal genomics, fermentation and downstream processing. This technology platform has resulted in Martek's development of a number of products, including the company's flagship product, life'sDHA™, a sustainable and vegetarian source of algal DHA (docosahexaenoic acid) important for brain, heart and eye health throughout life for use in infant formula, pregnancy and nursing products, foods and beverages, dietary supplements and animal feeds. The Company also produces life'sARA™ (arachidonic acid), an omega-6 fatty acid, for use in infant formula and growing-up milks. Martek's subsidiary, Amerifit Brands, develops, markets and distributes branded consumer health and wellness products and holds leading brand positions in all of its key product categories. Amerifit products are sold in most major mass, club, drug, grocery and specialty stores and include: Culturelle®, a leading probiotic supplement; AZO, the leading OTC brand addressing symptom relief and detection of urinary tract infections; and ESTROVEN®, the leading all-natural nutritional supplement brand addressing the symptoms of menopause. Martek currently has a number of nutritional health and wellness products under development that it plans to commercialize and distribute through Amerifit's distribution channels.
Martek's technology platform has also made it a sought-after partner on a range of groundbreaking projects in process, including the development of microbially-derived biofuels and the development of DHA-containing oilseeds. For more information on Martek Biosciences, visit http://www.martek.com/. For a complete list of life'sDHA™ and life'sARA™ products, visit http://www.lifesdha.com/. For more information about Amerifit Brands, visit www.amerifit.com.
MARTEK BIOSCIENCES CORPORATION
Summary Consolidated Financial Information
(Unaudited - $ in thousands, except per share data)Unaudited Condensed Consolidated Statements of Income DataThree months ended July 31, Nine months ended July 31,2010200920102009Revenues:Product sales
247,218Contract manufacturing and collaborations3,1922,79013,74810,390Total revenues117,16377,834330,887257,608Cost of revenues:Cost of product sales56,01141,129164,310137,337Cost of contract manufacturing and collaborations2,6472,67511,97710,101Total cost of revenues58,65843,804176,287147,438Gross margin58,50534,030154,600110,170Operating expenses:Research and development 8,4996,60424,38620,510Selling, general and administrative 18,89211,02749,59836,058Advertising and promotion 5,59841210,0721,353Amortization of intangible assets2,9831,5347,0224,910Acquisition costs484—3,472—Restructuring charge607—607—Other operating expenses300234505956Total operating expenses37,36319,81195,66263,787Income from operations21,14214,21958,93846,383Interest income (expense) and other, net(1,777)81(3,292)427Income before income tax provision19,36514,30055,64646,810Income tax provision 7,4795,37221,60017,259Net income
29,551Basic earnings per share
0.89Diluted earnings per share
0.89Shares used in computing basic earnings per share33,46833,23433,37633,191Shares used in computing diluted earnings per share33,61033,34633,54233,346Unaudited Condensed Consolidated Balance Sheets DataJuly 31,October 31, 20102009Assets:Cash and cash equivalents
141,063Short-term investments—7,301Accounts receivable, net66,41544,304Inventories, net110,751116,179Other current assets5,7765,240Property, plant and equipment, net249,825252,279Deferred tax asset25,76124,303Long-term investments4,6334,495Goodwill, intangibles and other long-term assets, net328,40494,653Total assets
689,817Liabilities and stockholders' equity:Accounts payable and accrued expenses
31,365Notes payable and other long-term obligations4,265810Deferred tax liability76,20010,091Deferred revenue 8,84911,407Stockholders' equity674,969636,144Total liabilities and stockholders' equity
689,817Unaudited Condensed Consolidated Cash Flow DataNine months ended July 30,20102009Operating activities:Net income
29,551Non-cash items53,44640,945Changes in operating assets and liabilities, net 12,201(30,494)Net cash provided by operating activities99,69340,002Investing activities:Cash paid for acquisition of Amerifit, net of cash acquired(200,743)—Sale of investments and marketable securities, net7,350100Expenditures for property, plant and equipment(13,171)(6,733)Capitalization of intangible assets(4,077)(6,129)Net cash used in investing activities(210,641)(12,762)Financing activities:Repayments of notes payable, term loan and other long-term obligations(75,162)(88)Proceeds of term loan75,000—Borrowings from revolving line of credit11,000—Repayments of borrowings from revolving line of credit(11,000)—Payment of debt issuance costs(3,944)—Proceeds (payments) from equity transactions, net512(302)Net cash used in financing activities(3,594)(390)Foreign currency translation adjustment1—Net change in cash and cash equivalents (114,541)26,850Cash and cash equivalents, beginning of period141,063102,495Cash and cash equivalents, end of period
129,345Table IMARTEK BIOSCIENCES CORPORATIONSEGMENT INFORMATION(Unaudited - $ in thousands)Three months ended July 31,Nine months ended July 31,2010200920102009Segment RevenuesBranded consumer health products
—Nutritional ingredients 93,36174,402277,392245,466Other3,5013,43215,18512,142Total
257,608Segment Income From OperationsBranded consumer health products
46,383Table IIMARTEK BIOSCIENCES CORPORATIONRECONCILIATION OF GAAP TO NON-GAAP NET INCOME MEASURE(Unaudited)The Company makes reference in this release to non-GAAP presentations of fiscal 2010 net income and diluted earnings per share that exclude expenses associated with the acquisition of Amerifit and the restructuring of the Winchester manufacturing site. We are providing this information to assist investors in comparing the results of the current periods to those in the prior year periods when these items were not present. We caution investors, however, that these non-GAAP results should only be considered in addition to results that are reported under current GAAP and should not be considered as a substitute for results that are presented under GAAP. Following is a schedule showing the reconciliation of net income and diluted earnings per share reported under GAAP to the non-GAAP financial measure included herein:Three months ended July 31,Nine months ended July 31,Historical Results, $ in thousands2010200920102009Net income, as reported under GAAP
29,551Add: acquisition costs, net of tax302—2,504—Add: restructuring charge, net of tax374—374—Add: inventory step-up, net of tax 149—1,219—Non-GAAP net income measure
29,551Three months ended July 31,Nine months ended July 31,Historical Results, $ per share2010200920102009Diluted earnings per share, as reported under GAAP
0.89Add: acquisition costs, net of tax.01—.07—Add: restructuring charge, net of tax.01—.01—Add: inventory step-up, net of tax .01—.04—Non-GAAP diluted earnings per share measure
1.14$0.89Forecasted Results, $ in millionsThree months ended October 31, 2010Net income, projected to be reported under GAAP
$(13.4) – (5.9) Add: projected restructuring charge, net of tax25.2 – 19.0Non-GAAP net income measure
$.8 – 13.1Forecasted Results, $ per shareThree months ended October 31, 2010Diluted earnings per share, projected to be reported under GAAP
(0.40) – (0.18) Add: projected restructuring charge, net of tax.75 – 0.57Non-GAAP diluted earnings per share measure
$.35 – 0.39CONTACTKyle StultsInvestor Relations(410) firstname.lastname@example.org
|SOURCE Martek Biosciences Corporation|
Copyright©2010 PR Newswire.
All rights reserved